Clinical trial • Phase III • Oncology

Artesunate for Cancer | Advanced cancer

Phase III trial of Artesunate for Cancer | Advanced cancer. 14 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Cancer | Advanced cancer
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
12-12-2024
First CTIS Authorization Date
30-01-2025

Trial design

Phase III trial across 2 sites in Spain.

Target Sample Size
14

Recruitment

Planned Sample Size
14
Recruitment Window Months
32

Geography

Total Number Of Sites
2
Total Number Of Participants
14

Spain

Earliest CTIS Part Ii Submission Date
12-12-2024
Latest Decision Or Authorization Date
30-01-2025
Processing Time Days
49
Number Of Sites
2
Number Of Participants
14

Sites

Site Name
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida
Department Name
Medical Oncology
Contact Person Name
Antonieta Salud
Contact Person Email
asaluds@hotmail.com
Site Name
Hospital De Sant Pau I Santa Tecla
Department Name
Medical Oncology
Contact Person Name
Vicente Valentí
Contact Person Email
vvalenti@xarxatecla.cat

Sponsor

Primary sponsor

Full Name
Hospital De Sant Pau I Santa Tecla
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
Artesunate
Active Substance
Artesunate
Modality
Small molecule
Investigational Product Name
Sulfasalazine
Active Substance
Sulfasalazine
Modality
Small molecule
Investigational Product Name
Polyunsaturated fatty acids
Active Substance
Polyunsaturated fatty acids
Modality
Small molecule
Investigational Product Name
Iron
Active Substance
Iron
Modality
Small molecule

Related trials

Other published trials that may interest you.